211 related articles for article (PubMed ID: 32569704)
21. Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes.
Katsumata K; Chono K; Sudo K; Shimizu Y; Kontani T; Suzuki H
Molecules; 2011 Aug; 16(9):7210-23. PubMed ID: 21869749
[TBL] [Abstract][Full Text] [Related]
22. Testing the sensitivities of noncognate inhibitors to varicella zoster virus thymidine kinase: implications for postherpetic neuralgia therapy with existing agents.
Yang L; Mo X; Yang H; Dai H; Tan F
J Mol Model; 2014 Jul; 20(7):2321. PubMed ID: 24961898
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.
Katsumata K; Chono K; Kato K; Ohtsu Y; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2013 Mar; 57(3):1339-46. PubMed ID: 23274658
[TBL] [Abstract][Full Text] [Related]
24. The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture.
Lawetz C; Liuzzi M
Antiviral Res; 1998 Jul; 39(1):35-46. PubMed ID: 9754948
[TBL] [Abstract][Full Text] [Related]
25. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Suzuki M; Okuda T; Shiraki K
Antiviral Res; 2006 Nov; 72(2):157-61. PubMed ID: 16797734
[TBL] [Abstract][Full Text] [Related]
26. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses.
Lowe DM; Alderton WK; Ellis MR; Parmar V; Miller WH; Roberts GB; Fyfe JA; Gaillard R; Ertl P; Snowden W
Antimicrob Agents Chemother; 1995 Aug; 39(8):1802-8. PubMed ID: 7486922
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of Helicase-Primase Inhibitor Amenamevir-Resistant Herpes Simplex Virus.
Sato Y; Suenaga T; Kobayashi M; Miyazaki N; Suzuki T; Ishioka K; Suzutani T
Antimicrob Agents Chemother; 2021 Sep; 65(10):e0049421. PubMed ID: 34228537
[TBL] [Abstract][Full Text] [Related]
28. Comparison of a DNA probe assay with the plaque reduction assay for measuring the sensitivity of herpes simplex virus and varicella-zoster virus to penciclovir and acyclovir.
Standring-Cox R; Bacon TH; Howard BA
J Virol Methods; 1996 Jan; 56(1):3-11. PubMed ID: 8690764
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of DNA synthesis in varicella-zoster virus-infected cells by BV-araU.
Machida H; Watanabe Y
Microbiol Immunol; 1991; 35(2):139-45. PubMed ID: 1653394
[TBL] [Abstract][Full Text] [Related]
30. Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus.
Ono N; Iwayama S; Suzuki K; Sekiyama T; Nakazawa H; Tsuji T; Okunishi M; Daikoku T; Nishiyama Y
Antimicrob Agents Chemother; 1998 Aug; 42(8):2095-102. PubMed ID: 9687413
[TBL] [Abstract][Full Text] [Related]
31. Broad-spectrum antiviral activity of the acyclic guanosine phosphonate (R,S)-HPMPG.
Terry BJ; Mazina KE; Tuomari AV; Haffey ML; Hagen M; Feldman A; Slusarchyk WA; Young MG; Zahler R; Field AK
Antiviral Res; 1988 Dec; 10(4-5):235-51. PubMed ID: 2852486
[TBL] [Abstract][Full Text] [Related]
32. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
Takada A; Katashima M; Kaibara A; Sawamoto T; Zhang W; Keirns J
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):365-70. PubMed ID: 27129009
[TBL] [Abstract][Full Text] [Related]
33. The effects of interferon-alpha and acyclovir on herpes simplex virus type-1 ribonucleotide reductase.
O'Brien WJ; Narasimhan J; Guy J; Tom P; Taylor JL
Antiviral Res; 1998 May; 38(2):107-16. PubMed ID: 9707373
[TBL] [Abstract][Full Text] [Related]
34. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
35. Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model.
Uhlig N; Donner AK; Gege C; Lange F; Kleymann G; Grunwald T
Antiviral Res; 2021 Nov; 195():105190. PubMed ID: 34666109
[TBL] [Abstract][Full Text] [Related]
36. Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.
Andrei G; Snoeck R
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672709
[TBL] [Abstract][Full Text] [Related]
37. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
[TBL] [Abstract][Full Text] [Related]
38. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Feb; 42(2):216-22. PubMed ID: 9527762
[TBL] [Abstract][Full Text] [Related]
39. Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
Luganini A; Sibille G; Mognetti B; Sainas S; Pippione AC; Giorgis M; Boschi D; Lolli ML; Gribaudo G
Antiviral Res; 2021 May; 189():105057. PubMed ID: 33716051
[TBL] [Abstract][Full Text] [Related]
40. [Contribution of the laboratory in case of resistance to acyclovir of herpes simplex and varicella zoster virus].
Morfin F; Frobert E; Thouvenot D
Ann Biol Clin (Paris); 2003; 61(1):33-40. PubMed ID: 12604384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]